What the Lawsuits Allege
The hair relaxer litigation involves women who allege that chemical hair straighteners and relaxers contain endocrine-disrupting chemicals that caused hormone-related cancers, most prominently uterine and endometrial cancer, along with ovarian cancer and conditions like fibroids. Plaintiffs allege the manufacturers failed to warn about these risks and did not adequately test the products. The defendants deny liability.
The claims gained momentum after a 2022 National Institutes of Health study reported that women who frequently used chemical straighteners had roughly double the risk of uterine cancer compared with non-users. The litigation has drawn particular attention because these products were heavily marketed to and used by Black women, who studies indicate face the greatest exposure.
The MDL and Its Defendants
The federal cases are consolidated as MDL 3060 in the Northern District of Illinois before Judge Mary Rowland, with more than 11,000 cases pending and the number still growing. This is a multidistrict litigation, not a class action, so each plaintiff keeps an individual case while pretrial matters are handled together. A separate state-court mass tort also proceeds in Pennsylvania.
Named defendants include major manufacturers such as L Oreal USA, Revlon, Strength of Nature, and others. The litigation has involved disputes over discovery, including the production of foreign regulatory records, and courts have allowed many of the cases against these companies to move forward past early dismissal attempts.
Where Things Stand
The litigation is in the bellwether phase. The court limited the first trial pool to cases involving uterine, endometrial, or ovarian cancer, narrowing a group of representative cases for early trials. A Science Day to educate the court on the alleged cancer link was scheduled for early 2026, followed by hearings on the reliability of expert testimony, which will determine whether the causation evidence can reach a jury.
The first federal trials are expected in the 2026 to 2027 window, and no global settlement has been reached. Because outcomes depend heavily on those expert rulings and early trials, there is no reliable figure for what an individual case may be worth, and deadlines vary by state, so a prompt individual assessment is the practical step.
How to Get Legal Help
If you or a family member fits the description here, a consultation with a lawyer who handles this specific litigation is the reliable next step. Deadlines vary by state and can be unforgiving, most of these firms offer a free review, and these cases are typically taken on contingency, so you pay nothing unless they recover for you.
To follow filings, trial outcomes, and any settlement news, bookmark this page and subscribe to LawsuitWatch alerts.
Free Legal Evaluation
Do You Qualify to File a Claim?
Our network of verified plaintiff attorneys offers free, no-obligation case evaluations. Contingency fee representation means you pay nothing unless you win.
Hair Relaxer Lawsuit: The Cancer Claims and Where They Stand: Frequently Asked Questions
Answers to the most common questions about this case and your legal options.
What do hair relaxer lawsuits allege?
That chemical hair straighteners contain endocrine-disrupting chemicals that caused hormone-related cancers, mainly uterine and endometrial cancer, along with ovarian cancer and other conditions, and that manufacturers failed to warn. The defendants deny liability.
What is the science behind the claims?
A 2022 National Institutes of Health study reported that frequent users of chemical straighteners had roughly double the uterine cancer risk of non-users. Whether that evidence is reliable enough for trial is being tested through expert hearings in the MDL.
Where are the cases handled?
Federal cases are consolidated as MDL 3060 in the Northern District of Illinois before Judge Mary Rowland, with more than 11,000 pending, plus a separate state mass tort in Pennsylvania. It is an MDL, not a class action.
Is there a hair relaxer settlement?
No global settlement has been reached. The litigation is in the bellwether phase, with the first federal trials expected in the 2026 to 2027 window, and outcomes will depend heavily on expert-evidence rulings.
Who may qualify?
Generally a woman who used chemical hair relaxers regularly for years and was later diagnosed with uterine, endometrial, or ovarian cancer. Deadlines vary by state, so a prompt individual assessment matters.